We don't know what kind of impact it will have on survival, but it clearly offers a clinical benefit. It provides us with another treatment we can use before chemotherapy. Patients will be enrolled for a year. Prostate cancer is the most common cancer, excluding nonmelanoma skin cancers, in American men, according to the American Cancer Society. The organization estimates that 180,400 new cases of prostate cancer will be diagnosed in the United States this year.
Prostate cancer is the second leading cause of cancer death in men, exceeded only by lung cancer.
About 31,900 men in the United States will die of this disease during 2000, according to the American Cancer Society.